Clinical Trials Sponsored by Cardero Therapeutics, Inc.

Total 2990 results

Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Orexigen Therapeutics, Inc

Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Healthy

United States
Orexigen Therapeutics, Inc

Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight

United States
INSYS Therapeutics Inc

Withdrawn

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days

Neoplasms

United States
Avalo Therapeutics, Inc.

Completed

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Chronic Refractory Cough

United States
Pearl Therapeutics, Inc.

Completed

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

COPD

United States
Repros Therapeutics Inc.

Completed

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Effect of Treatment on Bone Mineral Density

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Terminated

Study to Evaluate Menses Induction in Women Administered Proellex

Amenorrhea

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Drug Interactions

United States
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

Mexico
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Pharmacokinetics | Tolerability

United States
Repros Therapeutics Inc.

Completed

A Safety and Pharmacokinetic Study of Proellex® (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Determination of the Lowest, Safe and Effective Dose of Proellex

Amenorrhea

United States
Repros Therapeutics Inc.

Completed

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
Repros Therapeutics Inc.

Completed

A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

Uterine Leiomyomata

Poland
Tarsa Therapeutics, Inc.

Completed

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

Phase 1 Pharmacodynamic Study

United States
Revance Therapeutics, Inc.

Terminated

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Skin Aging

United States
Nivalis Therapeutics, Inc.

Completed

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

Asthma

United States
OcuNexus Therapeutics, Inc.

Completed

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)

Diabetic Foot Ulcers

Russian Federation, United States, Ukraine
Immunomic Therapeutics, Inc.

Completed

A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

Allergic Rhinoconjunctivitis

United States
Repros Therapeutics Inc.

Completed

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Secondary Hypogonadism
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Uterine Fibroids
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
Melinta Therapeutics, Inc.

Completed

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

Streptococcal Infections | Abscess | Staphylococcal Skin Infections | Infectious Skin Diseases | Bacterial Skin Diseases

United States
Nivalis Therapeutics, Inc.

Completed

Safety and Tolerability Study of N6022 in Healthy Subjects

Healthy

United States
Avalo Therapeutics, Inc.

Completed

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

Acute Cough

Chile, Peru
Revance Therapeutics, Inc.

Completed

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Vaginal Administration

Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules

United States
Ortek Therapeutics, Inc.

Completed

Comparison of Early Caries Detection in Children Utilizing an Electrical Conductance Device and the Gold Standard of Visual-tactile Technique.

Dental Caries in Children

Venezuela
Tarsa Therapeutics, Inc.

Completed

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women (ORACAL)

Osteoporosis, Postmenopausal

United States, United Kingdom, Bulgaria, Hungary, Poland, South Africa
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
INSYS Therapeutics Inc

Completed

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

Pain | Cancer

United States, India, Canada
Mati Therapeutics Inc.

Completed

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Glaucoma | Ocular Hypertension (OH)

United States
Mati Therapeutics Inc.

Completed

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension (CORE)

Ocular Hypertension | Glaucoma

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

Fragile X Syndrome

United States
Tobira Therapeutics, Inc.

Completed

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Oraya Therapeutics, Inc.

Unknown

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (ENDEAVOUR)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | Wet Macular Degeneration

United Kingdom
INSYS Therapeutics Inc

Completed

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

Pain

United States

3

Subscribe